Musikantow, Daniel R.
Reddy, Vivek Y.
Skalsky, Ivo
Shaburishvili, Tamaz
van Zyl, Martin
O’Brien, Barry
Coffey, Ken
Reilly, John
Neuzil, Petr
Asirvatham, Samuel
de Groot, Joris R.
Funding for this research was provided by:
Horizon 2020 (879499)
Article History
Received: 8 June 2023
Accepted: 30 July 2023
First Online: 10 August 2023
Declarations
:
: The study was approved by the Czech National Competent Authority SUKL and the local ethic committees and was performed in full accordance with the principle of the “Declaration of Helsinki” (2013).
: All patients underwent informed consent in advance of treatment. All events were reviewed by an independent Clinical Events Committee (CEC).
: Daniel Musikantow, Martin Van Zyl, and Ivo Skalsky have nothing relevant to this manuscript to disclose. Mayo Clinic has pursued protection of intellectual property including in the form of patents and patent applications, naming Dr. Asirvatham as inventor, related to the information disclosed herein, and licensed to AtriAN Medical Ltd. Joris de Groot received research grants through his institution from Atricure, Bayer, Boston Scientific, Daiichi Sankyo, Johnson&Johnson and Medtronic, and honoraria/consultancy/speakers fees from AtriaN, Atricure Inc., Bayer, Berlin Chemie, Biotronik, CVOI, Daiichi Sankyo, Medtronic, Menarini, Novartis, and Servier. Vivek Reddy is a consultant to Atrian he also has disclosures with companies unrelated to this manuscript, which are listed in the Supplement. Petr Neuzil and Tamaz Shaburishvili have received grant support from AtriAN. Barry O’Brien, Ken Coffey, and John Reilly and are employees of AtriAN.